Literature DB >> 16044100

Determinants of mycophenolic acid levels after renal transplantation.

Richard Borrows1, Gary Chusney, Anthony James, Jose Stichbury, Jen Van Tromp, Tom Cairns, Megan Griffith, Nadey Hakim, Adam McLean, Andrew Palmer, Vassilios Papalois, David Taube.   

Abstract

There are data suggesting an association between mycophenolic acid (MPA) levels and acute rejection and toxicity in renal transplant recipients treated with mycophenolate mofetil (MMF), and therefore, knowledge of factors determining MPA levels may aid in accurate adjustment of MMF dosage. A total of 4970 samples taken 12 hours postdose were analyzed for MPA by immunoassay at regular intervals from the first week posttransplantation in 117 renal transplant patients immunosuppressed with MMF and tacrolimus in a steroid-sparing regimen (prednisolone for the first 7 days only). MPA levels rose in the first 3 months and stabilized thereafter; dose-normalized MPA levels rose throughout the first 12 months and subsequently stabilized. Multivariate analysis by means of a population-averaged linear regression showed positive associations between MPA level and total daily dose (P < 0.001) but not individual dose or total daily dose corrected for body weight. Positive associations were also seen with serum albumin (P = 0.01), tacrolimus trough level (P = 0.01), and female gender (P = 0.002). The association with tacrolimus levels diminished with time. Negative associations were seen between MPA level and higher estimated creatinine clearance (P < 0.001), and also with increasing alanine transaminase levels (P = 0.002), the use of oral antibiotics (P < 0.001), and infective diarrhea (P < 0.001). The latter findings may be related to changes in enterohepatic recirculation of MPA. Many clinical variables show associations with trough MPA levels. An understanding of these factors may aid therapeutic monitoring of MMF.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16044100     DOI: 10.1097/01.ftd.0000167885.17280.6f

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  10 in total

1.  Large scale analysis of routine dose adjustments of mycophenolate mofetil based on global exposure in renal transplant patients.

Authors:  Franck Saint-Marcoux; Soizic Vandierdonck; Aurélie Prémaud; Jean Debord; Annick Rousseau; Pierre Marquet
Journal:  Ther Drug Monit       Date:  2011-06       Impact factor: 3.681

2.  Mycophenolic acid exposure after administration of mycophenolate mofetil in the presence and absence of cyclosporin in renal transplant recipients.

Authors:  Dirk R Kuypers; Henrik Ekberg; Josep Grinyó; Björn Nashan; Flavio Vincenti; Paul Snell; Richard D Mamelok; Rene M Bouw
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 3.  The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation.

Authors:  Nicolas Picard; Pierre Marquet
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-03-25       Impact factor: 4.481

4.  Polymorphisms of UGT1A9 and UGT2B7 influence the pharmacokinetics of mycophenolic acid after a single oral dose in healthy Chinese volunteers.

Authors:  Dong Guo; Liang-Fang Pang; Yang Han; Hong Yang; Guo Wang; Zhi-Rong Tan; Wei Zhang; Hong-Hao Zhou
Journal:  Eur J Clin Pharmacol       Date:  2012-10-10       Impact factor: 2.953

5.  Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8 2 variant allele.

Authors:  Jean-Baptiste Woillard; Jean-Philippe Rerolle; Nicolas Picard; Annick Rousseau; Mireille Drouet; Eliza Munteanu; Marie Essig; Pierre Marquet; Yann Le Meur
Journal:  Br J Clin Pharmacol       Date:  2010-06       Impact factor: 4.335

6.  Sustained renal response to mycophenolate mofetil and CNI taper promotes survival in liver transplant patients with CNI-related renal dysfunction.

Authors:  A Kornberg; B Küpper; K Thrum; B Krause; P Büchler; J Kornberg; A Sappler; A Altendorf-Hofmann; J Wilberg; H Friess
Journal:  Dig Dis Sci       Date:  2010-09-08       Impact factor: 3.199

Review 7.  Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease.

Authors:  Azrin N Abd Rahman; Susan E Tett; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2013-05       Impact factor: 6.447

8.  Ciprofloxacin blocked enterohepatic circulation of diclofenac and alleviated NSAID-induced enteropathy in rats partly by inhibiting intestinal β-glucuronidase activity.

Authors:  Ze-Yu Zhong; Bin-Bin Sun; Nan Shu; Qiu-Shi Xie; Xian-Ge Tang; Zhao-Li Ling; Fan Wang; Kai-Jing Zhao; Ping Xu; Mian Zhang; Ying Li; Yang Chen; Li Liu; Lun-Zhu Xia; Xiao-Dong Liu
Journal:  Acta Pharmacol Sin       Date:  2016-05-16       Impact factor: 6.150

9.  Population pharmacogenetic pharmacokinetic modeling for flip-flop phenomenon of enteric-coated mycophenolate sodium in kidney transplant recipients.

Authors:  Nayoung Han; Hwi-yeol Yun; In-Wha Kim; Yoon Jung Oh; Yon Su Kim; Jung Mi Oh
Journal:  Eur J Clin Pharmacol       Date:  2014-08-28       Impact factor: 2.953

Review 10.  Pharmacokinetic Drug-Drug Interactions Between Immunosuppressant and Anti-Infective Agents: Antimetabolites and Corticosteroids.

Authors:  Edward T Van Matre; Gowri Satyanarayana; Robert L Page 2nd; Marilyn E Levi; JoAnn Lindenfeld; Scott W Mueller
Journal:  Ann Transplant       Date:  2018-01-23       Impact factor: 1.530

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.